CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Primary Prevention of Heart Failure in Women Heart Failure and Atrial Fibrillation, Like Fire and Fury The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Dilated cardiomyopathy: so many cardiomyopathies! Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure

Clinical TrialFebruary 6, 2018, Volume 137, Issue 6

JOURNAL:Circulation Article Link

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study

M .Kosiborod, CVD-REAL Investigators and Study Group. Keywords: SGLT2 inhibitor; death; diabetes mellitus; heart failure; observational studies

FULL TEXT PDF